Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Ankylosing spondylitis; Axial spondyloarthritis
- Focus Registrational; Therapeutic Use
- Acronyms COAST-W
- Sponsors Eli Lilly and Company
- 03 Jun 2023 Post-hoc results (n=587) from COAST-V, COAST-X, COAST-W studies presented at the 24th Annual Congress of the European League Against Rheumatism.
- 15 Feb 2023 Results(n=932: from the COAST program at 3 years, 1 year of the originating studies (COAST-V/-W/-X) and 2 years of COAST-Y) assessing safety and efficacy of ixekizumab in patients with axial spondyloarthritis published in The Journal of Rheumatology
- 01 Feb 2023 Results assessing the test-retest reliability, construct validity, known groups discrimination, and responsiveness of the Assessment of the SpondyloArthritis international Society Health Index (ASAS HI) to evaluate functioning, disability, and health in patients with radiographic axial spondyloarthritis (r-axSpA) from (COAST-V, N = 341; COAST-W, N = 316) studies, published in The Journal of Rheumatology.